![Troels Krarup Hansen](https://ddeacademy.dk/wp-content/uploads/2024/08/TroelsKrarup_SH_-aspect-ratio-276-352-276x352.jpg)
Danish Diabetes and Endocrine Academy (DDEA) is headed by a Board of Directors (BoD) of seven members with a well-balanced and broad representation of stakeholders, with regard to gender, age, national geography, and sector.
The BoD includes representation from early-career researchers, senior researchers, and clinicians, as well as universities, hospitals, and the life science industry, across diabetes and classical endocrinology fields.
The members have competence and experience as board members/chairpersons, researchers, or clinicians in diabetes and classical endocrinology fields, education and talent development, innovation and entrepreneurship, fundraising, public-private partnerships, impact assessment, and Novo Nordisk Foundation-funded initiatives and strategies.
The principal tasks of the BoD are to:
define and decide the overall strategy and the strategy for DDEA’s four key activity areas and oversee its implementation
approve the annual accounts and budget, the annual programme for DDEA activities, and make the final decision on grant allocations
perform an annual evaluation of DDEA and its organisation, including impact assessment of the success criteria, key performance indicators, and other evaluation factors to decide whether the strategy for future activities needs adjusting.
Further information can be found in the Terms of References of the DDEA Board of Directors.
EAN: 5798 0022 30642
Reference: 1025 0006
CVR: 29 19 09 09